logo

LEXX

Lexaria Bioscience·NASDAQ
--
--(--)
--
--(--)
5.85 / 10
Netural

Financial evaluation shows fair fundamentals scoring 5.8/10. Advantageous factors: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, offset by weaknesses in PB-ROE and Days sales outstanding. Overall judgment: moderate.

Fundamental(5.85)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-2.82
Score3/3
Weight20.92%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value52.05
Score2/3
Weight1.79%
1M Return1.11%
Days sales outstanding
Value133.32
Score0/3
Weight-7.39%
1M Return-5.18%
Profit-MV
Value0.44
Score2/3
Weight16.68%
1M Return8.45%
Net income-Revenue
Value0.15
Score2/3
Weight16.69%
1M Return8.45%
PB-ROE
Value0.74
Score0/3
Weight4.98%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value42.48
Score2/3
Weight-1.67%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value52.05
Score2/3
Weight0.69%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight30.92%
1M Return13.15%
Cash-MV
Value0.14
Score2/3
Weight16.40%
1M Return8.41%
Is LEXX fundamentally strong?
  • LEXX scores 5.85/10 on fundamentals and holds a Fair valuation at present. Backed by its -44.76% ROE, 0.00% net margin, -1.67 P/E ratio, 3.99 P/B ratio, and -14.00% earnings growth, these metrics solidify its Netural investment rating.